Buscar resultados de ensayos clínicos
Coagulation Protein Disorders - 25 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study) Condición:
Intervenciones: |
Enrolling by invitation |
Nombre del estudio: A Study of ProMetic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia Condición: Hypoplasminogenemia Fecha: 2016-02-12 Intervenciones: Biological: Plasminogen (human) intravenous ProMetic Plasminogen(human) intravenous |
Completed |
Nombre del estudio: A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency Condición:
Fecha: 2014-12-04 Intervenciones: Biological: Plasminogen (Human) Intravenous Plasma-derived purified plasminogen formulated for intraveno |
Recruiting |
Nombre del estudio: Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products Condición: Hemophilia A Fecha: 2016-11-24 Intervenciones:
|
Recruiting |
Nombre del estudio: A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B Condición:
Fecha: 2017-02-14 Intervenciones:
|
Recruiting |
Nombre del estudio: A Gene Transfer Study for Hemophilia A Condición: Hemophilia A Fecha: 2016-12-16 Intervenciones: Genetic: SPK-8011 A novel, bio-engineered, recombinant adeno-associated viral vector carrying human fact |
Terminated |
Nombre del estudio: Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A Condición: Hemophilia A Fecha: 2011-09-13 Intervenciones: Biological: OBI-1 intravenous infusion, up to every 2-3 hours for the first 24 hours of treatment |
Completed |
Nombre del estudio: Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A Condición: Hemophilia A Fecha: 2010-08-06 Intervenciones: Biological: OBI-1 Intravenous infusion |
Withdrawn |
Nombre del estudio: Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B Condición: Hemophilia B Fecha: 2013-11-14 Intervenciones: Biological: IB1001 Prophylaxis (during Treatment and Conti |
Completed |
Nombre del estudio: BAY14-2222 Prophylaxis and Joint Function Improvement (Adults) Condición:
Fecha: 2007-12-21 Intervenciones: Drug: Kogenate (BAY14-2222) One group two treatment schedules, first on-demand then switch to prophylaxi |